Dec 14, 2015
CorMedix Announces Enrollment and Dosing of First Patient in Phase 3 Neutrolin® Trial in Hemodialysis
Nov 4, 2015
CorMedix, Inc. to Announce Third Quarter 2015 Results on November 12, 2015
Oct 5, 2015
CorMedix Inc. Abstracts Highlighting the Economic Burden of Central Venous Catheter Complications to be Presented at Kidney Week 2015
Sep 24, 2015
CorMedix Inc. to Present at Dawson James Securities Growth Stock Conference
Aug 31, 2015
CorMedix Inc. Abstracts Accepted for Presentation at American Society of Nephrology Kidney Week 2015
Aug 6, 2015
CorMedix Inc. Announces Janet D. Dillione Will Join Board of Directors
Jul 17, 2015
CorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study
Jun 22, 2015
CorMedix Inc. to Join Russell Global and Russell 3000 Indexes
Jun 17, 2015
CorMedix Inc. Receives Positive Feedback from FDA for Neutrolin® Clinical Trial Protocol for Oncology Patients
Jun 1, 2015
CorMedix Presents Neutrolin® Post Marketing Surveillance Data at European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Conference
May 5, 2015
CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015
Apr 23, 2015
CorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences
Apr 9, 2015
CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore
Mar 20, 2015
CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants
Mar 9, 2015
CorMedix Clarifies Extension of Expiration Date for Publicly Traded Warrants
Mar 4, 2015
CorMedix Inc. Provides Multiple Strategic Business Updates
Jan 29, 2015
FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.’s Lead Product Candidate in the U.S.
Jan 15, 2015
CorMedix Inc. Receives Fast Track Designation For Neutrolin®
Dec 4, 2014
CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin®
Dec 3, 2014
Neutrolin Label Expansion Approved in Germany